N/A
Completed N=120
Ameparomo Capsules 250 mg Drug Use Investigation
Intestinal Amebiasis
Source: ClinicalTrials.gov NCT02680665 ↗
Enrolled (actual)
120
Serious AEs
0.0%
Results posted
Jan 2020
Primary outcomePrimary: Number of Participants With Adverse Drug Reactions — 15; 0 Particpants
Summary
This Study is intended to evaluate the safety and effectiveness of Ameparomo Capsules 250 mg under actual medical practice.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Adverse Drug Reactions |
15; 0 | — |
| SECONDARY Proportion of Cyst Negative |
98.1 | — |
| SECONDARY Overall Clinical Response Rate |
99.0 | — |
Eligibility Criteria
Inclusion Criteria
- Patients with no history of using this product
Exclusion Criteria
- No exclusion criteria are set out in this study.
Data sourced from ClinicalTrials.gov (NCT02680665). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.